文献速递心血管胸部MR

REPAIR研究:马西腾坦对肺动脉高压患者右心室结构与功能的影响

The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension.
PubMed 文献 · JACC Cardiovasc Imaging · 2021-11-17

REPAIR为52周开放标签单臂多中心4期研究,评估马西腾坦10 mg(联用或不联用磷酸二酯酶5抑制剂)对肺动脉高压患者右心室重构与功能及血流动力学的影响,采用心脏磁共振与右心导管。最终分析(n=71)显示第26周右心室每搏量增加12 mL、肺血管阻力降低38%,第52周右心室功能与结构改善维持。

要点

  • 心脏磁共振测量的右心室每搏量第26周较基线增加12 mL(96%置信水平:8.4-15.6 mL;P < 0.0001)。
  • 右心导管测量的肺血管阻力第26周较基线降低38%(99%置信水平:31%-44%;P < 0.0001)。
  • 第52周右心室与左心室心脏磁共振变量及功能参数的改善维持。

核心结论

  • 在本研究背景下,肺动脉高压患者接受马西腾坦治疗后右心室功能与结构及心肺血流动力学获得显著且具有临床意义的改善。
  • 第52周时右心室功能与结构的改善维持。

研究设计与样本

  • REPAIR为52周、开放标签、单臂、多中心、4期研究,评估马西腾坦10 mg(联用或不联用磷酸二酯酶5抑制剂)对右心室重构与功能及心肺血流动力学的影响。
  • 主要终点为基线至第26周心脏磁共振测定的右心室每搏量变化和右心导管测定的肺血管阻力变化;疗效分析纳入两个主要终点均有基线与第26周数据的全部患者。
  • 预设中期分析纳入42例时两个主要终点均达到,入组停止并宣布研究阳性;最终分析n=71,安全性分析n=87。

关键影像表现/征象

  • 第26周心脏磁共振显示右心室每搏量较基线增加12 mL(96%置信水平:8.4-15.6 mL;P < 0.0001)。
  • 第26周右心导管显示肺血管阻力较基线降低38%(99%置信水平:31%-44%;P < 0.0001)。
  • 第26周次要与探索性心脏磁共振(右心室和左心室)、血流动力学及功能终点也观察到显著正向变化。
  • 第52周心脏磁共振右心室和左心室变量及功能参数的改善维持。

诊断标准与关键数值

  • 疗效评估采用心脏磁共振测定右心室每搏量、右心导管测定肺血管阻力,主要终点为基线至第26周的变化。
  • 右心室每搏量变化12 mL(96%置信水平:8.4-15.6 mL;P < 0.0001);肺血管阻力变化降低38%(99%置信水平:31%-44%;P < 0.0001)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The REPAIR (Right vEntricular remodeling in Pulmonary ArterIal hypeRtension) study evaluated the effect of macitentan on right ventricular (RV) and hemodynamic outcomes in patients with pulmonary arterial hypertension (PAH), using cardiac magnetic resonance (CMR) and right heart catheterization (RHC).

BACKGROUND: RV failure is the primary cause of death in PAH. CMR is regarded as the most accurate noninvasive method for assessing RV function and remodeling and CMR measures of RV function and structure are strongly prognostic for survival in patients with PAH. Despite this, CMR is not routinely used in PAH clinical trials.

METHODS: REPAIR was a 52-week, open-label, single-arm, multicenter, phase 4 study evaluating the effect of macitentan 10 mg, with or without phosphodiesterase type-5 inhibition, on RV remodeling and function and cardiopulmonary hemodynamics. Primary endpoints were change from baseline to week 26 in RV stroke volume, determined by CMR; and pulmonary vascular resistance, determined by RHC. Efficacy measures were assessed for all patients with baseline and week 26 data for both primary endpoints.

RESULTS: At a prespecified interim analysis in 42 patients, both primary endpoints were met, enrollment was stopped, and the study was declared positive. At final analysis (n = 71), RV stroke volume increased by 12 mL (96% confidence level: 8.4-15.6 mL; P < 0.0001) and pulmonary vascular resistance decreased by 38% (99% confidence level: 31%-44%; P < 0.0001) at week 26. Significant positive changes were also observed in secondary and exploratory CMR (RV and left ventricular), hemodynamic, and functional endpoints at week 26. Improvements in CMR RV and left ventricular variables and functional parameters were maintained at week 52. Safety (n = 87) was consistent with previous clinical trials.

CONCLUSIONS: In the context of this study, macitentan treatment in patients with PAH resulted in significant and clinically-relevant improvements in RV function and structure and cardiopulmonary hemodynamics. At 52 weeks, improvements in RV function and structure were sustained. (REPAIR: Right vEntricular remodeling in Pulmonary ArterIal hypeRtension [REPAIR]; NCT02310672).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Vonk Noordegraaf, Channick, Cottreel, et al. The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2021. PMID: 34801462. doi:10.1016/j.jcmg.2021.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。